Evaluating Diamyd’s Phase II/III Data & Trial to Highlight Next Steps in Antigen-Specific Therapeutic Development & Provide Direction for Ongoing Trials
8:30 am - Wednesday 24th March 2027
- Reviewing the Phase II/III clinical data across the most advanced antigen-specific programs to distinguish mechanism of action from execution and trial design, providing greater confidence in assessing which approaches are most likely to deliver meaningful clinical benefit
- Unpacking the dosing, timing, and site-selection decisions in the Phase III trial to highlight endpoints and spotlight what could be changed in hindsight
- Setting out the priorities for the next year of ASIT development based on direct latestage trial experience to focus the field’s collective effort on the antigen selection, patient stratification, and delivery choices most likely to succeed
